Cargando…

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry

OBJECTIVE: To describe the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents, evaluate prognostic factors of MDA achievement and identify the most common unmet criteria among MDA achievers. DESIGN: Biologic Treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Proton, Zummer, Michel, Bessette, Louis, Baer, Philip, Haraoui, Boulos, Chow, Andrew, Kelsall, John, Kapur, Suneil, Rampakakis, Emmanouil, Psaradellis, Eliofotisti, Lehman, Allen J, Nantel, Francois, Osborne, Brendan, Tkaczyk, Cathy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629663/ https://www.ncbi.nlm.nih.gov/pubmed/28855200 http://dx.doi.org/10.1136/bmjopen-2017-016619

Ejemplares similares

Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis
por: Rahman, Proton, et al.
Publicado: (2016)

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
por: Bhoi, Peter, et al.
Publicado: (2017)

Efficacy of BIO K+ CL1285((®)) in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study
por: Sampalis, John, et al.
Publicado: (2010)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly
por: Sampalis, John S., et al.
Publicado: (2018)

Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial
por: Pope, Janet, et al.
Publicado: (2012)

Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017)

Pseudoseptic Arthritis: An Initial Presentation of Underlying Psoriatic Arthritis
por: Paul, Prodip, et al.
Publicado: (2021)

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
por: Bessette, Louis, et al.
Publicado: (2023)

Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol
por: Canzoni, Marco, et al.
Publicado: (2018)

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
por: Haraoui, Boulos, et al.
Publicado: (2015)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis
por: Ooms, Alexander, et al.
Publicado: (2023)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study
por: Kragsnaes, Maja Skov, et al.
Publicado: (2021)

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study
por: Højgaard, Pil, et al.
Publicado: (2016)

Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
por: Rotar, Ziga, et al.
Publicado: (2020)

Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial
por: Kragsnaes, Maja Skov, et al.
Publicado: (2018)

Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort
por: Vallejo-Yagüe, Enriqueta, et al.
Publicado: (2022)

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)
por: Kleinrensink, Nienke J, et al.
Publicado: (2022)

Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial
por: Proft, Fabian, et al.
Publicado: (2021)

Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic Diseases
por: Mougui, Ahmed, et al.
Publicado: (2023)

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
por: Uhrenholt, Line, et al.
Publicado: (2019)

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
por: Movahedi, Mohammad, et al.
Publicado: (2023)

Measuring herpes zoster disease burden in São Paulo, Brazil: a clinico-epidemiological single-center study
por: Toniolo-Neto, João, et al.
Publicado: (2018)

The Psoriatic Arthritis Experience in Saudi Arabia from the Rheumatologist and Patient Perspectives
por: Alhomood, Ibrahim, et al.
Publicado: (2023)

Classification of osteoarthritis phenotypes by metabolomics analysis
por: Zhang, Weidong, et al.
Publicado: (2014)

Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
por: Hald, Jannie D, et al.
Publicado: (2023)

Translation, cross-cultural adaptation and validation of the traditional Chinese intermittent and constant osteoarthritis pain (ICOAP) questionnaire for knee osteoarthritis
por: Sit, Regina Wing Shan, et al.
Publicado: (2019)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Psoriatic arthritis: prospects for the future
por: Hackett, Simon, et al.
Publicado: (2022)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
por: Maksymowych, Walter P., et al.
Publicado: (2023)

Gout and the risk for incident heart failure and systolic dysfunction
por: Krishnan, Eswar
Publicado: (2012)

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
por: Kastbom, Alf, et al.
Publicado: (2012)

A qualitative interview study: patient accounts of medication use in early rheumatoid arthritis from symptom onset to early postdiagnosis
por: Townsend, Anne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gaorcue8fnchug9v0jtf6dr8v5